Hearne Michael S

About Hearne Michael S

Michael S. Hearne is an अमेरिकी corporate finance executive closely associated with La Jolla Pharmaceutical Company, where he served as Chief Financial Officer and Secretary. His career has been centered on finance, accounting, and governance responsibilities within life sciences and other high-compliance environments. Publicly available biographical information indicates that, since 2015, he has also served as Chief Financial Officer of Tang Capital Management, a life sciences-focused investment firm. In addition, he has held multiple roles at Odonate Therapeutics since 2015, including Chief Financial Officer beginning in 2018. Prior to those positions, he was a partner at Weaver & Tidwell, LLP from 2014 to 2015, and earlier in his career he worked in public accounting at Coopers & Lybrand. Hearne’s educational background includes a B.S. in accounting and a Master of Accountancy with a taxation concentration from Brigham Young University. He is also a Certified Public Accountant, inactive, in the state of California. Together, these credentials point to a career built around financial reporting, tax, audit readiness, internal controls, and regulatory discipline—capabilities that are especially relevant in the pharmaceutical sector, where public-company compliance and capital allocation are critical. At La Jolla Pharmaceutical Company, Hearne’s role as CFO placed him at the center of financial stewardship, investor-facing disclosure, and public-company governance. In a biotechnology setting, a CFO is typically responsible for managing liquidity, supporting strategic financing decisions, and helping guide the company through the demands of U.S. securities reporting and board oversight. Hearne’s combination of accounting firm experience, partnership-level advisory work, and senior finance roles in life sciences suggests a profile suited to companies operating in complex, development-stage or commercialization-stage environments. While the publicly available sources do not provide a detailed record of specific high-profile decisions personally attributable to him, his career path indicates substantial experience in capital markets, financial control, and executive oversight for healthcare-related enterprises. Overall, Michael S. Hearne appears as a seasoned finance executive whose background aligns closely with the governance and reporting needs of U.S.-listed pharmaceutical companies.